Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James K Sheffield

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Review of Neurotherapeutics|June 15, 2007
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's diseaseJames K Sheffield, Joseph Jankovic
Parkinsonism & Related Disorders|June 10, 2009
Motor overflow and mirror dystoniaOraporn Sitburana, Laura Jui Chen Wu, James K Sheffield, et al.
Journal of Comparative Effectiveness Research|January 18, 2020
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosisElyse Swallow, Oscar Patterson-Lomba, Lei Yin, et al.
European Journal of Neurology|July 22, 2021
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosisBruce A C Cree, Rachel Maddux, Amit Bar-Or, et al.
Multiple Sclerosis and Related Disorders|January 17, 2021
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MSJohn DeLuca, Sven Schippling, Xavier Montalban, et al.
Annals of Clinical and Translational Neurology|March 27, 2026
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial ParticipantsRalf Gold, Krzysztof W Selmaj, Regina Berkovich, et al.
Multiple Sclerosis and Related Disorders|April 23, 2021
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development programKrzysztof W Selmaj, Jeffrey A Cohen, Giancarlo Comi, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Review of Neurotherapeutics|June 15, 2007
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's diseaseJames K Sheffield, Joseph Jankovic
Parkinsonism & Related Disorders|June 10, 2009
Motor overflow and mirror dystoniaOraporn Sitburana, Laura Jui Chen Wu, James K Sheffield, et al.
Journal of Comparative Effectiveness Research|January 18, 2020
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosisElyse Swallow, Oscar Patterson-Lomba, Lei Yin, et al.
European Journal of Neurology|July 22, 2021
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosisBruce A C Cree, Rachel Maddux, Amit Bar-Or, et al.
Multiple Sclerosis and Related Disorders|January 17, 2021
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MSJohn DeLuca, Sven Schippling, Xavier Montalban, et al.
Annals of Clinical and Translational Neurology|March 27, 2026
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial ParticipantsRalf Gold, Krzysztof W Selmaj, Regina Berkovich, et al.
Multiple Sclerosis and Related Disorders|April 23, 2021
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development programKrzysztof W Selmaj, Jeffrey A Cohen, Giancarlo Comi, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, et al.
Pageof 2